Nasdaq
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates disease burden of prostate cancer by quantifying the hotspots on bone scans.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $339.4M | $425.2M | $935.1M | $1.3B | $1.5B | $1.5B |
| Gross profit | $138.8M | $187.7M | $581.7M | $709.5M | $988.3M | $942.0M |
| Operating income | -$4.2M | -$60.8M | $36.2M | $364.6M | $457.0M | $310.8M |
| Net income | -$13.5M | -$71.3M | $28.1M | $326.7M | $312.4M | $233.6M |
| Diluted EPS | -$0.25 | -$1.06 | $0.40 | $4.65 | $4.36 | $3.41 |
| Operating cash flow | $16.4M | $53.9M | $281.8M | $305.3M | $544.8M | $390.1M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | 40.9% | 44.1% | 62.2% | 54.7% | 64.4% | 61.1% |
| Operating margin | -1.2% | -14.3% | 3.9% | 28.1% | 29.8% | 20.2% |
| Net margin | -4.0% | -16.8% | 3.0% | 25.2% | 20.4% | 15.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $394.1M | $378.7M | $391.1M | $372.8M | $378.0M | $384.0M | $406.8M | $377.3M |
| Gross profit | $255.8M | $242.1M | $248.5M | $237.7M | $241.0M | $222.4M | $240.9M | $230.9M |
| Operating income | $102.7M | $133.7M | $113.9M | $102.1M | $88.0M | $43.6M | $77.2M | $81.3M |
| Net income | $62.1M | $131.1M | -$11.8M | $72.9M | $78.8M | $27.8M | $54.1M | $118.4M |
| Diluted EPS | $0.88 | $1.79 | -$0.18 | $1.02 | $1.12 | $0.41 | $0.86 | $1.80 |
| Operating cash flow | $84.7M | $175.1M | $157.7M | $107.6M | $87.1M | $105.3M | $90.2M | $125.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 64.9% | 63.9% | 63.5% | 63.8% | 63.8% | 57.9% | 59.2% | 61.2% |
| Operating margin | 26.1% | 35.3% | 29.1% | 27.4% | 23.3% | 11.4% | 19.0% | 21.6% |
| Net margin | 15.8% | 34.6% | -3.0% | 19.6% | 20.8% | 7.2% | 13.3% | 31.4% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-14 | Heino Mary Anne· Executive Chair and CEO | Tax withholding | 1,227 | $96.67 | $118,614.09 | filing |
| 2026-05-14 | Ber Gerard | Tax withholding | 381 | $96.67 | $36,831.27 | filing |
| 2026-05-14 | Ber Gerard | Tax withholding | 381 | $96.67 | $36,831.27 | filing |
| 2026-05-14 | Maeusli Heinz Christoph | Award | 4,137 | $0.00 | $0.00 | filing |
| 2026-05-14 | LENO SAM R | Award | 4,137 | $0.00 | $0.00 | filing |
| 2026-05-14 | Pruden Gary J | Award | 4,137 | $0.00 | $0.00 | filing |
| 2026-05-14 | Ber Gerard | Award | 4,137 | $0.00 | $0.00 | filing |
| 2026-05-14 | Thrall James H | Award | 4,137 | $0.00 | $0.00 | filing |
| 2026-05-14 | EASTLAND JULIA MARIE | Award | 4,137 | $0.00 | $0.00 | filing |
| 2026-05-14 | Baylor-Henry Minnie | Award | 4,137 | $0.00 | $0.00 | filing |
| 2026-05-14 | McHugh Julie | Award | 4,137 | $0.00 | $0.00 | filing |
| 2026-05-14 | Morrow Phuong Khanh | Award | 4,137 | $0.00 | $0.00 | filing |
| 2026-04-17 | Niedzwiecki Daniel· See Remarks | Tax withholding | 1,911 | $83.82 | $160,180.02 | filing |
| 2026-03-05 | Niedzwiecki Daniel· See Remarks | Tax withholding | 1,283 | $76.31 | $97,905.73 | filing |
| 2026-03-05 | Marshall Robert J. Jr.· CFO and Treasurer | Tax withholding | 1,182 | $76.31 | $90,198.42 | filing |
| 2026-03-05 | Morgan Amanda Michelle· Chief Commercial Officer | Tax withholding | 595 | $76.31 | $45,404.45 | filing |
| 2026-03-05 | Brown Kimberly· Chief Accounting Officer | Tax withholding | 133 | $76.31 | $10,149.23 | filing |
| 2026-03-05 | Dinkelborg Ludger· See Remarks | Award | 20,966 | $0.00 | $0.00 | filing |
| 2026-03-05 | Niedzwiecki Daniel· See Remarks | Award | 36,692 | $0.00 | $0.00 | filing |
| 2026-03-05 | Marshall Robert J. Jr.· CFO and Treasurer | Award | 38,002 | $0.00 | $0.00 | filing |
| 2026-03-05 | Brown Kimberly· Chief Accounting Officer | Award | 6,158 | $0.00 | $0.00 | filing |
| 2026-03-05 | Morgan Amanda Michelle· Chief Commercial Officer | Award | 26,208 | $0.00 | $0.00 | filing |
| 2026-03-02 | Heino Mary Anne· Executive Chair and CEO | Tax withholding | 41,916 | $76.30 | $3.2M | filing |
| 2026-03-02 | Marshall Robert J. Jr.· CFO and Treasurer | Tax withholding | 10,652 | $76.30 | $812,747.60 | filing |
| 2026-03-02 | Niedzwiecki Daniel· See Remarks | Tax withholding | 8,259 | $76.30 | $630,161.70 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.